GAB2 and non-small cell lung carcinoma: In contrast, the c-MET amplified human non-small cell lung carcinoma cell line NCI-H441 serving as positive control showed strong and dose-dependent reduction in phosphorylated c-MET levels as well as in phosphorylated downstream effectors Gab2, Akt, MEK1/2, and p42/44 MAPK (Erk1/2) upon OMO-1 treatment (Supplementary Fig. 2b).